NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 6.9% - What's Next?

Key Points

• NewAmsterdam Pharma shares fell 6.9% to about $23.87, with trading volume down 84% from the average session. The stock remains below its 50-day and 200-day moving averages.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $49.73, despite mixed ratings including one sell recommendation.
• The company missed quarterly EPS estimates, reporting a loss of $0.52 per share versus the expected $0.48 loss, while revenue exceeded forecasts. Insiders have sold 270,000 shares worth approximately $7.76 million over the past 90 days.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) was down 6.9% during trading on Wednesday . The company traded as low as $24.25 and last traded at $23.8690. Approximately 167,541 shares traded hands during trading, a decline of 84% from the average session volume of 1,045,328 shares. The stock had previously closed at $25.63.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NAMS shares. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an "outperform" rating and a $58.00 target price for the company. Jefferies Financial Group reiterated a "buy" rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. HC Wainwright reissued a "buy" rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday. Weiss Ratings restated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Finally, Royal Bank Of Canada decreased their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.73.

NewAmsterdam Pharma Trading Down 8.9%

The firm has a market cap of $2.79 billion, a P/E ratio of -10.82 and a beta of 0.09. The business's 50-day moving average is $29.34 and its two-hundred day moving average is $31.45.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. On average, analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Kooij sold 105,000 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the sale, the chief accounting officer directly owned 24,353 shares of the company's stock, valued at $738,870.02. This trade represents a 81.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Johannes Kastelein sold 125,000 shares of the firm's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $26.91, for a total value of $3,363,750.00. Following the completion of the sale, the insider owned 69,302 shares in the company, valued at $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 270,000 shares of company stock valued at $7,757,450 in the last 90 days. Insiders own 12.74% of the company's stock.

Institutional Trading of NewAmsterdam Pharma

A number of large investors have recently modified their holdings of NAMS. Engineers Gate Manager LP bought a new stake in NewAmsterdam Pharma in the 2nd quarter valued at about $662,000. Squarepoint Ops LLC boosted its stake in NewAmsterdam Pharma by 113.9% during the 2nd quarter. Squarepoint Ops LLC now owns 92,026 shares of the company's stock valued at $3,119,000 after purchasing an additional 49,005 shares during the period. Arizona State Retirement System grew its position in NewAmsterdam Pharma by 34.6% in the 2nd quarter. Arizona State Retirement System now owns 16,656 shares of the company's stock worth $564,000 after purchasing an additional 4,281 shares during the last quarter. California State Teachers Retirement System grew its position in NewAmsterdam Pharma by 4,105.5% in the 2nd quarter. California State Teachers Retirement System now owns 2,284,796 shares of the company's stock worth $77,432,000 after purchasing an additional 2,230,467 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 6.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company's stock valued at $613,033,000 after purchasing an additional 1,145,128 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.